06.22.06
MGI Pharma received approval from the FDA for Dacogen for the treatment of adult patients with myelodysplastic syndromes (MDS). This new drug to combat MDS is the first high potency new chemical entity (NCE) which was developed and produced by fee-for-service provider Ferro Pfanstiehl Laboratories, Inc. Ferro Pfanstiehl provided API development, validation, clinical trial material and commercial production of Dacogen for Injection.
"This success validates Ferro Pfanstiel's foresight in developing a business strategy and platform that anticipates the needs of its specialized client base in the pharmaceutical and biopharmaceutical markets," said Peter Thomas, Ferro vice president of organic specialties. "Dacogen is one of many opportunities we have in our pipeline to bring fast-tracked, specialized drugs to market; these drugs provide therapies for relatively small patient populations with life-threatening diseases."
Ferro Pfanstiehl is producing commercial quantities of Dacogen and continues to work closely with MGI Pharma as it conducts further clinical trials to evaluate additional therapeutic uses for Dacogen.
"This success validates Ferro Pfanstiel's foresight in developing a business strategy and platform that anticipates the needs of its specialized client base in the pharmaceutical and biopharmaceutical markets," said Peter Thomas, Ferro vice president of organic specialties. "Dacogen is one of many opportunities we have in our pipeline to bring fast-tracked, specialized drugs to market; these drugs provide therapies for relatively small patient populations with life-threatening diseases."
Ferro Pfanstiehl is producing commercial quantities of Dacogen and continues to work closely with MGI Pharma as it conducts further clinical trials to evaluate additional therapeutic uses for Dacogen.